Clinical trial
MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
NCT00070837 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00070837 |
|---|---|
| Title | MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer |
| Official title | A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen-Independent Prostate Cancer |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | MLN2704 (DM1 conjugated monoclonal antibody MLN591) |
| Enrollment | 46 |
| Start date | Oct 1, 2003 |
| Completion | Oct 1, 2004 |
| First posted | Oct 13, 2003 |
| Last update posted | Jul 13, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: